A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
A phase 3 trial of Encorafenib, Binimetinib, Pembrolizumab in melanoma, run by Pfizer, active and no longer recruiting.
Overview
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma is a phase 3 interventional study registered as NCT04657991 by Pfizer, with 257 participants enrolled, started 2021-01-15 and due to reach its primary completion in 2026-10-30. Interventions recorded: Encorafenib, Binimetinib, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Shares Binimetinib, Encorafenib, Melanoma.
- TrialPhase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung
Shares Binimetinib, Encorafenib.
- TrialA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic
Shares Encorafenib, Pfizer (incl. Seagen), Pembrolizumab.
- TrialCOLUMBUS
Shares Binimetinib, Encorafenib, Melanoma.
- TrialThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu
Shares Pfizer (incl. Seagen), Pembrolizumab.
- CompanyPierre Fabre
Shares Binimetinib, Encorafenib, Pfizer (incl. Seagen).
- PairingBRAF inhibitor + MEK inhibitor
Shares Encorafenib, Melanoma.
- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Pfizer (incl. Seagen), Pembrolizumab.